37. 膿疱性乾癬（汎発型） Generalised pustular psoriasis Clinical trials / Disease details

臨床試験数 : 79 / 薬物数 : 57 - (DrugBank : 21) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102

24 trials found

diseases per page:

Showing 1 to 10 of 24 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05670821 (ClinicalTrials.gov)	April 1, 2023	2/1/2023	PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms	Post-marketing Surveillance of SpesolimabI.V. Infusion in Improvement of Generalized Pustular Psoria ...	Generalized Pustular Psoriasis	Drug: Spesolimab	Boehringer Ingelheim	NULL	Not yet recruiting	18 Years	N/A	All	38		Japan
2	NCT05239039 (ClinicalTrials.gov)	March 15, 2022	3/2/2022	An Expanded Access Program in China to Provide Spesolimabto People With a Flare-up in Generalized Pu ...	Multi-centre, Open-label, Expanded Access Program of 900mg Intravenous (i.v.) Spesolimabin Patients ...	Generalized Pustular Psoriasis	Drug: spesolimab	Boehringer Ingelheim	NULL	Recruiting	18 Years	75 Years	All	50	Phase 3	China
3	JPRN-jRCT2071210127	18/02/2022	23/02/2022	An Expanded Access trial in Japan to provide spesolimabto people with a flare-up in Generalized Pust ...	Multi-centre, open-label, expanded access trial of spesolimabi.v. in patients with generalized pustu ...	Generalized Pustular Psoriasis (GPP)	Drug: BI 655130 (Spesolimab) / Solution for infusion	Yamada Nobuko	NULL	Recruiting	>= 20age old	<= 75age old	Both	3	N/A	Japan
4	NCT05200247 (ClinicalTrials.gov)	February 17, 2022	11/1/2022	An Expanded Access Trial in Japan to Provide Spesolimabto People With a Flare-up in Generalized Pust ...	Multi-centre, Open-label, Expanded Access Trial of Spesolimabi.v. in Patients With Generalized Pustu ...	Generalized Pustular Psoriasis	Drug: spesolimab	Boehringer Ingelheim	NULL	Active, not recruiting	18 Years	75 Years	All	11	Phase 3	Japan
5	EUCTR2018-003080-56-ES (EUCTR)	07/02/2022	14/12/2021	A 5-year study to test BI 655130 in patients with GeneralizedPustular Psoriasis who took part in pre ...	An open-label, long term extension study to assess the safety andefficacy of BI 655130 treatment in ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim España S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 2	United States;Philippines;Taiwan;Greece;Thailand;Spain;Ukraine;Russian Federation;Chile;Israel;Colom ...
6	JPRN-jRCT2041210087	01/11/2021	20/10/2021	A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in pr ...	An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in ...	Generalized Pustular Psoriasis (GPP)	Drug: BI 655130 (Spesolimab) / Solution for infusion Drug: BI 655130 (Spesolimab) / Solution for inje ...	Yamada Nobuko	NULL	Recruiting	>= 12age old	<= 75age old	Both	4	Phase 2	Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Egypt;France;Georgi ...
7	EUCTR2018-003080-56-BG (EUCTR)	08/09/2021	30/07/2021	A 5-year study to test BI 655130 in patients with GeneralizedPustular Psoriasis who took part in pre ...	An open-label, long term extension study to assess the safety andefficacy of BI 655130 treatment in ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	150	Phase 2	United States;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Israel;Chile;Russian Federation;Colom ...
8	EUCTR2018-003081-14-HR (EUCTR)	26/08/2021	03/12/2021	A study to test whether BI 655130 (Spesolimab) prevents flare-ups in patients with Generalized Pustu ...	Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	98	Phase 2	United States;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Russian Federation;Chile;Israel;Colom ...
9	EUCTR2018-003081-14-BG (EUCTR)	17/05/2021	14/04/2021	A study to test whether BI 655130 (Spesolimab) prevents flare-ups in patients with Generalized Pustu ...	Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	98	Phase 2	United States;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Israel;Chile;Russian Federation;Colom ...
10	EUCTR2018-003081-14-PL (EUCTR)	24/09/2020	01/06/2020	A study to test whether BI 655130 (Spesolimab) prevents flare-ups in patients with Generalized Pustu ...	Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim RCV GmbH & Co KG	NULL	Not Recruiting			Female: yes Male: yes	98	Phase 2	United States;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Israel;Chile;Russian Federation;Colom ...

First Previous1 2 3Next Last